A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Phase 3 Recruiting 408 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Timeline

Start: 2025-09-03
Primary completion: 2028-01
Completion: 2028-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1905	Monoclonal antibody	—	—

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Summary

Timeline

Drugs

Indications